Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Autor: Lesimple, Thierry, Maio, Michele, Linette, Gerald, Mortier, Laurent, Svane, Inge Marie, Schachter, Jacob, Brown, Michael, Hersey, Peter, Barrow, Catherine, Kudchadkar, Ragini, Dutriaux, Caroline, Song, Xinni, Quaglino, Pietro, Queirolo, Paola, Meier, Friedegund, Stroyakovskiy, Daniil, Guillot, Bernard, Romero, Pablo Luis Ortiz, Bastholt, Lars, Garbe, Claus, Grange, Florent, Mohr, Peter, Algazi, Alain, Bechter, Oliver, Hernberg, Micaela, Loquai, Carmen, Meiss, Frank, Chiarion Sileni, Vanna, Bar-Sela, Gil, Fitzharris, Bernard, Saiag, Philippe, Arnault, Jean-Philippe, Simon, Jan-Christoph, Stephens, Rosalie, Baurain, Jean-Francois, Lebbe, Célèste, Combemale, Patrick, Dummer, Reinhard, Hauschild, Axel, Parente, Phillip, Yamazaki, Naoya, Milhem, Mohammed, Leccia, Marie-Thérèse, Geoffrois, Lionel, Kretschmer, Lutz, Dunwoodie, Elaine, Walker, John, Lotem, Michal, Hendler, Daniel, Mackiewicz, Andrzej, Sekulovic, Lidija, Dzienis, Marcin, Hospers, Geke A.P., Siano, Marco, Hassel, Jessica, Corrie, Philippa, Passos, Maria-Jose, Levin, Max, Hoeller, Christoph, Machet, Laurent, Hallmeyer, Sigrun, Waterston, Ashita, Descamps, Vincent, Kiecker, Felix, Aarts, Maureen, Schmidt, Henrik, Raimundo, Ana, Nyakas, Marta, Lacour, Jean-Philippe, Berking, Carola, Ferrucci, Pier Francesco, Jameson, Michael, Kim, Kevin, Yokota, Kenji, Kerger, Joseph, Aubin, François, Groenewegen, Gerard, Kapiteijn, Helena, Boehncke, Wolf-Henning, Utikal, Jochen, Casasola, Richard, Marshall, Ernest, Ferraresi, Virginia, Richtig, Erika, Matkovic, Suzana, Inozume, Takashi, Crook, Timothy, McNeil, Catriona, Kiyohara, Yoshio, Avril, Marie-Francoise, Hein, Rüdiger, Terheyden, Patrick, Nathan, Paul, Aoi, Jun, Skytta, Tanja, Jouary, Thomas, Takenouchi, Tatsuya, Straume, Oddbjorn, Martins, César, Mukhametshina, Guzel, Bottomley, Andrew ^*, Coens, Corneel, Mierzynska, Justyna, Blank, Christian U, Mandalà, Mario, Long, Georgina V, Atkinson, Victoria G, Dalle, Stéphane, Haydon, Andrew M, Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S, Sandhu, Shahneen, Puig, Susana, Ascierto, Paolo A, Larkin, James, Lorigan, Paul C, Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus J M, Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, van Akkooi, Alexander C J, Krepler, Clemens, Ibrahim, Nageatte, Marreaud, Sandrine, Kicinski, Michal, Suciu, Stefan, Robert, Caroline, Eggermont, Alexander M M

Publikováno v: In The Lancet Oncology May 2021 22(5):655-664

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial

Autor: Carlino, Matteo S., Long, Georgina V., Schadendorf, Dirk, Robert, Caroline, Ribas, Antoni, Richtig, Erika, Nyakas, Marta, Caglevic, Christian, Tarhini, Ahmed, Blank, Christian, Hoeller, Christoph, Bar-Sela, Gil, Barrow, Catherine, Wolter, Pascal, Zhou, Honghong, Emancipator, Kenneth, Jensen, Erin H., Ebbinghaus, Scot, Ibrahim, Nageatte, Daud, Adil

Publikováno v: In European Journal of Cancer September 2018 101:236-243

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Autor: Robert, Caroline, Schachter, Jacob, Long, Georgina V, Arance, Ana, Grob, Jean Jacques, Mortier, Laurent, Daud, Adil, Carlino, Matteo S, McNeil, Catriona, Lotem, Michal, Larkin, James, Lorigan, Paul, Neyns, Bart, Blank, Christian U, Hamid, Omid, Mateus, Christine, Shapira-Frommer, Ronnie, Kosh, Michele, Zhou, Honghong, Ibrahim, Nageatte, Ebbinghaus, Scot, Ribas, Antoni, Cebon, Jonathan, Hersey, Peter, Long, Georgina, Millward, Michael, Walpole, Euan, Höller, Christoph, Kehrer, Helmut, Richtig, Erika, Schmuth, Matthias, Baurain, Jean-François, Wolter, Pascal, Butler, Marcus, McWhirter, Elaine, Miller, Wilson, Petrella, Teresa, Acevedo, Alejandro, Caglevic, Christian, Morales, Luisa, Sanchez, Jesús, Yepes, Andres, Zambrano, Angela Regina, Avril, Marie-Francoise, Dutriaux, Caroline, Guilot, Bernard, Lacour, Jean-Phillippe, Leccia, Marie-Therese, Legoupil, Delphine, Lebbe, Celeste, Machet, Laurent, Berking, Carola, Loquai, Carmen, Mohr, Peter, Schadendorf, Dirk, Utikal, Jochen, Bar-Sela, Gil, Blank, Christian, Barrow, Catherine, Fitzharris, Bernie, Kersten, Christian, Nyakas, Marta, Straume, Oddbjørn, Berrocal, Alfonso, Cortes, Javier, Espinosa, Enrique, Lopez-Martin, Jose, Martin-Algarra, Salvador, Masucci, Giuseppe, Papworth, Karin, Ullenhag, Gustav, Brown, Ewan, Chao, David, Evans, Thomas, Middleton, Mark, Skaria, Sunil, Steven, Neil, Agarwala, Sanjiv, Bhatia, Shailender, Gangadhar, Tara, Gonzalez, Rene, Kumar, Pallavi, Kuzel, Timothy, Lutzky, Jose, O'Day, Steven, Perry, David, Pecora, Andrew, Puzanov, Igor, Slezak, Karen, Sznol, Mario, Tarhini, Ahmad, Weiss, Geoffrey

Publikováno v: The New England journal of medicine. 372(26)

BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with adva

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::253c3a098f8b65fc28937f4824ea480c
https://pubmed.ncbi.nlm.nih.gov/25963092